TL;DR
Researchers have identified SLC17A1 and SLC17A3 as key transporters responsible for excreting N-lactoyl-phenylalanine (Lac-Phe) in urine. This discovery sheds light on how this exercise-induced metabolite, linked to appetite and body weight regulation, is processed by the kidneys.
What Problem Does This Paper Address?
N-lactoyl-phenylalanine (Lac-Phe) is an intriguing metabolite produced from lactate and phenylalanine, known to suppress appetite and reduce body weight, especially after exercise. While its physiological roles are becoming clearer, the molecular mechanisms governing its transport across cell membranes, particularly its excretion, remained largely unknown. Specifically, how Lac-Phe moves from the bloodstream or tissues into the urine for elimination was a significant gap in our understanding. This paper aims to identify the specific transporters responsible for this renal excretion.
Methods
The researchers employed a multi-pronged approach:
- In vitro cell culture experiments: They used HEK293T cells, a common cell line for transporter studies, and transfected them with various SLC17 family members (SLC17A1-4). They then measured Lac-Phe levels in the cell culture media to assess efflux activity.
- Metabolomics: Untargeted metabolomics was used to identify changes in metabolites within the cell culture media after transfection, confirming Lac-Phe as a key substrate for SLC17A1 and SLC17A3.
- Genetic association studies in humans: They analyzed existing human metabolome-genome association data to find correlations between genetic variations in the SLC17A1-4 locus and urinary Lac-Phe levels.
- Animal models (Mice): They generated and studied knockout mice lacking either SLC17A1 or SLC17A3. They measured Lac-Phe levels in urine and plasma of these mice and compared them to wild-type littermates.
- Exercise studies: Human participants underwent a Wingate sprint test, and their urine Lac-Phe levels were measured before and after exercise to observe dynamic changes.
- Mass Spectrometry (LC-MS/MS): This technique was crucial for identifying and confirming the chemical structure of Lac-Phe and distinguishing it from a similar metabolite, 1-carboxyethylphenylalanine.
Datasets
- Human Metabolome-Genome Association Data: The study utilized data from previous genome-wide association studies (GWAS) that identified associations between urinary metabolites and genetic loci.
- GTEx (Genotype-Tissue Expression) Project: This dataset was used to examine the tissue-specific expression patterns of SLC17 family members in humans.
- BioGPS: This portal was used to access mouse gene expression data, specifically for examining SLC17 family member expression in different mouse tissues.
- Tabula Muris: A single-cell RNA sequencing dataset of mouse tissues was used to investigate the expression of SLC17A1/3 in specific kidney cell types.
Key Insights and Ideas
- Lac-Phe is a substrate for SLC17 transporters: The study provides strong evidence that SLC17A1 and SLC17A3 are not just associated with Lac-Phe but actively transport it.
- Kidney-specific excretion: SLC17A1 and SLC17A3 are highly expressed in the kidney, aligning with their role in urinary Lac-Phe excretion.
- Decoupling of urine and plasma pools: Knockout mice for SLC17A1/3 showed reduced urinary Lac-Phe but normal plasma levels, indicating that the mechanisms for excreting Lac-Phe into urine are distinct from those regulating its levels in the blood. This suggests separate pathways for different bodily fluids.
- Exercise dynamically increases urinary Lac-Phe: The human exercise study revealed a significant, albeit temporary, increase in urinary Lac-Phe levels after intense exercise, highlighting the dynamic regulation of this metabolite's excretion.
- Structural confirmation is critical: The paper emphasizes the importance of rigorous chemical structure determination, as a similar metabolite (1-carboxyethylphenylalanine) was initially misidentified, underscoring the need for techniques like LC-MS/MS and authentic standards.
Key Results
- Overexpression of SLC17A1 and SLC17A3 in HEK293T cells led to a 2-fold and 5-fold increase in extracellular Lac-Phe, respectively, while SLC17A2 and SLC17A4 showed no significant effect.
- Genetic ablation of SLC17A1 in mice reduced urine Lac-Phe levels by approximately 30%, and SLC17A3 knockout mice showed a 40% reduction.
- In humans, urinary Lac-Phe levels showed a strong genetic association with the SLC17A1-4 locus.
- After a Wingate sprint test in humans, urine Lac-Phe levels increased by 2-fold one hour post-exercise and returned to baseline by 2 hours.
- Plasma Lac-Phe levels remained unchanged in both SLC17A1-KO and SLC17A3-KO mice, supporting the decoupling of urine and plasma pools.
Limitations and Future Work
- Functional redundancy: The partial reduction in urine Lac-Phe in single knockout mice suggests functional redundancy between SLC17A1 and SLC17A3, and potentially other transporters. The authors suggest generating double knockout mice (SLC17A1/3-KO) or even mice deficient in all four SLC17 transporters to fully elucidate these mechanisms.
- Non-renal transporters: While SLC17A1/3 are key for renal excretion, the paper notes that they don't significantly impact plasma Lac-Phe levels. This implies that other, yet unidentified, transporters are responsible for Lac-Phe efflux from its production sites into the bloodstream. Future work should focus on uncovering these transporters.
- Cell-type specificity: The magnitude of SLC17-mediated Lac-Phe efflux varied depending on the cell type (e.g., kidney epithelial cells vs. macrophages), suggesting that the specific transporter and cell context are important.
- Broader substrate identification: The study suggests that SLC17 transporters likely handle many other endogenous substrates beyond Lac-Phe and urate, given their broad association with various metabolites in human genetic studies. Identifying these additional substrates is a promising avenue for future research.
- Inhibitor development: The development of potent, selective, and in vivo-active SLC17A1/3 inhibitors could provide valuable tools for further pharmacological interrogation of this pathway.
Summary updated